600196 Stock Overview Shanghai Fosun Pharmaceutical (Group) Co., Ltd. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Competitors Price History & Performance
Summary of share price highs, lows and changes for Shanghai Fosun Pharmaceutical (Group) Historical stock prices Current Share Price CN¥25.69 52 Week High CN¥30.44 52 Week Low CN¥20.38 Beta 0.72 1 Month Change -2.10% 3 Month Change 10.69% 1 Year Change 5.94% 3 Year Change -48.33% 5 Year Change -3.42% Change since IPO 912.73%
Recent News & Updates See more updates
Does This Valuation Of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) Imply Investors Are Overpaying? Dec 18
There May Be Some Bright Spots In Shanghai Fosun Pharmaceutical (Group)'s (SHSE:600196) Earnings Nov 05
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Oct 30
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024 Sep 30
Investor sentiment improves as stock rises 24% Sep 30
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Election of Chen Yuqing as Non-Executive Director Sep 27
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces in Relation to the Approval for Drug Registration of Licensed Product Sep 09
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Aug 28
Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) Is Paying Out Less In Dividends Than Last Year Aug 03
Dividend reduced to CN¥0.27 Aug 02
Here's Why Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) Has A Meaningful Debt Burden Jul 28
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Board and Board Committee Changes Jul 01
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024 Jun 28 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Approves Final Cash Dividend for the Year Ended 31 December 2023, Payable on 23 August 2024
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Executive and Committee Changes Jun 19
Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Annual General Meeting, Jun 26, 2024 May 26
Market Still Lacking Some Conviction On Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) May 23
Consensus EPS estimates fall by 12% May 06
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Just Missed EPS By 15%: Here's What Analysts Think Will Happen Next May 01
First quarter 2024 earnings: EPS and revenues miss analyst expectations Apr 30
We Think You Can Look Beyond Shanghai Fosun Pharmaceutical (Group)'s (SHSE:600196) Lackluster Earnings Apr 02
Consensus EPS estimates fall by 17% Apr 02
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024 Mar 29
New minor risk - Profit margin trend Mar 28
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) announces an Equity Buyback for CNY 200 million worth of its shares. Mar 28 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) announces an Equity Buyback for CNY 200 million worth of its shares. Mar 27
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023 Mar 26
Is Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) A Risky Investment? Mar 18
Are Investors Undervaluing Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) By 48%? Feb 26
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024 Dec 29
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) acquired additional 40% stake in Shanghai Fujian Equity Investment Fund Management Co., Ltd. from Shanghai Fosun Health Industry Holding Company Limited for CNY 22.2 million. Nov 01
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Oct 31
Jiangsu Xingsheng Xinhui Pharmaceutical Co., Ltd. Receives Approval from the National Medical Products Administration of China for the Clinical Trial of XS-03 Tablets Oct 25 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that it expects to receive CNY 497.7664 million in funding Oct 20
Price target decreased by 13% to CN¥32.65 Oct 10
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023 Sep 30
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces National Medical Products Administration Accepts New Drug Application of Cisplatin Injection Sep 08
Price target decreased by 7.0% to CN¥37.41 Sep 06
Second quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.42 in 2Q 2022) Aug 30
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q2, 2023 Results on Aug 29, 2023 Aug 12
Palatin Technologies, Inc.'s Vyleesi Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study Aug 09
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023 Jun 28
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Approval for Drug Registration of Fosun Kite Biotechnology Co., Ltd Jun 27
Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Annual General Meeting, Jun 28, 2023 May 26
Full year 2022 earnings: EPS and revenues miss analyst expectations Mar 29
BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China Dec 24
Fosun Reportedly Planning Sale of Gland Pharma Nov 30 China's Fosun Reportedly Said to Mull Sale of India's $3.6 Billion Gland Pharma
Less than half of directors are independent Nov 16
Consensus forecasts updated Nov 06
Investor sentiment improved over the past week Nov 06
Shandong Liancheng Precision Manufacturing Co., Ltd (SZSE:002921) completed the acquisition of 3.9858% stake in Shanghai Shen-li High Tech Co., Ltd. from Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) and Shanghai Fulian Technology Co., Ltd. Nov 03
Third quarter 2022 earnings: Revenues exceed analyst expectations Oct 31
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q3, 2022 Results on Oct 28, 2022 Oct 18
Executive Vice Chairman recently bought CN¥391k worth of stock Sep 28
Now 20% undervalued after recent price drop Sep 26
Executive Chairman recently bought CN¥887k worth of stock Sep 15
Investor sentiment deteriorated over the past week Sep 08
Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 31
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q2, 2022 Results on Aug 29, 2022 Aug 16
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Appoints Wen Deyong as an Executive Director Aug 11
Price target decreased to CN¥46.32 Jun 05 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Executive Appointments
Price target decreased to CN¥50.41 May 31
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Recommends Final Dividend for 2021, Dispatch of Cheques for the 2021 Final Dividend Payable on H Shares Is 4 July 2022 May 20
Consensus forecasts updated May 03
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Apr 28
Price target decreased to CN¥56.55 Apr 27
Less than half of directors are independent Apr 27
Investor sentiment deteriorated over the past week Apr 13
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q1, 2022 Results on Apr 26, 2022 Apr 13
Price target decreased to CN¥56.55 Mar 30
Price target decreased to CN¥58.66 Mar 24
Investor sentiment improved over the past week Mar 15
Insilico Medicine Achieves Its First Major Milestone in Fosun Pharma Collaboration with the Nomination of Preclinical Candidate for QPCTL Feb 18
Investor sentiment deteriorated over the past week Jan 27
Fosun Pharma and Insilico Medicine Announces A Strategic, Ai-Driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets Jan 12
Third quarter 2021 earnings released: EPS CN¥0.42 (vs CN¥0.30 in 3Q 2020) Oct 27
Tianjin Kingyork Group Co., Ltd. signed the Equity Transfer agreement to acquire an additional 25.0011% stake in Tianjin Pharmaceutical Group Co., Ltd. from Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) for CNY 1.4 billion. Aug 24
Second quarter 2021 earnings released: EPS CN¥0.64 (vs CN¥0.43 in 2Q 2020) Aug 24
Director Xiaoliang Xu has joined 4th company board Aug 19
Director Xiaoliang Xu has joined 4th company board Aug 19
Director Xiaoliang Xu has joined 4th company board Aug 19
Director Xiaoliang Xu has joined 4th company board Aug 19
Director Xiaoliang Xu has joined 4th company board Aug 19
Price target increased to CN¥65.58 Aug 09
Price target increased to CN¥64.03 Aug 02
Investor sentiment deteriorated over the past week Jul 27
Price target increased to CN¥57.92 Jul 16
Sisram Medical (Tianjin) Limited completed the acquisition of Shanghai Foshion Medical System Co., Ltd. from Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) and Qianda (Tianjin) International Trading Co., Ltd. Jul 15
Investor sentiment deteriorated over the past week Jul 08 Shareholder Returns 600196 CN Pharmaceuticals CN Market 7D -1.0% -1.0% 0.4% 1Y 5.9% -3.0% 12.3%
See full shareholder returns
Return vs Market: 600196 underperformed the CN Market which returned 9.8% over the past year.
Price Volatility Is 600196's price volatile compared to industry and market? 600196 volatility 600196 Average Weekly Movement 5.3% Pharmaceuticals Industry Average Movement 7.4% Market Average Movement 8.8% 10% most volatile stocks in CN Market 13.0% 10% least volatile stocks in CN Market 5.8%
Stable Share Price: 600196 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600196's weekly volatility (5%) has been stable over the past year.
About the Company Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. The company’s product pipeline includes HLX15, a recombinant anti-CD38 human monoclonal antibody injection for treatment of multiple myeloma; HLX13, an anti-CTLA-4 human monoclonal antibody for the treatment of melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural mesothelioma, and esophageal squamous cell cancer; SZEY-2108 for the treatment of carbapenem resistant enterobacteriaceae (CRE) infection; XH-S003 for the treatment of IgA nephropathy and other glomerular diseases; HLX43, an antibody-drug for the treatment of metastatic solid tumors; XS-03 for the treatment of RAS-mutated advanced solid tumor; OP0595, a nacubactam for the treatment of aerobic gram-negative bacteria; XH-S002 for the treatment of ischemic stroke and transient ischemic attack which are in Phase I; HLX26, anti-LAG-3 humanized monoclonal antibody injection for the treatment of metastatic colorectal cancer; FCN-338 for the treatment of myeloid malignancies; FCN-159 for the treatment of langerhans cell histiocytosis; HLX208, a BRAF V600E inhibitor for the treatment of non-small cell lung cancer which are in phase II; FS-1502, a HER2 humanized monoclonal antibody-monomethyl auristatin F injection for the treatment of HER2-positive locally advanced or metastatic breast cancer; FCN-159 for the treatment of neurofibromatosis; ET-26, a methoxyetomidate hydrochloride for the treatment of general anesthesia which are in phase III.
Show more Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Fundamentals Summary How do Shanghai Fosun Pharmaceutical (Group)'s earnings and revenue compare to its market cap? 600196 fundamental statistics Market cap CN¥61.48b Earnings (TTM ) CN¥2.11b Revenue (TTM ) CN¥41.61b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 600196 income statement (TTM ) Revenue CN¥41.61b Cost of Revenue CN¥21.83b Gross Profit CN¥19.78b Other Expenses CN¥17.67b Earnings CN¥2.11b
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 0.80 Gross Margin 47.55% Net Profit Margin 5.08% Debt/Equity Ratio 55.0%
How did 600196 perform over the long term?
See historical performance and comparison Dividends
1.1% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/24 06:05 End of Day Share Price 2024/12/24 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is covered by 31 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ling Zhang BNP Paribas Securities (Asia) Wai Chak Yuen BOCI Research Ltd. Yang Huang BofA Global Research
Show 28 more analysts 
